Biohit Oyj Stock Exchange Release December 17, 2015 at 3:30 pm. local time (EET)
Biohit Oyj’s board has decided in the final meeting of the year that the company will change its financial reporting schedule from the beginning of 2016. In the future, Biohit Oyj will publish financial reviews twice a year. This is a change to the previously published schedule (4.12.2015 Biohit's Financial Reporting and Annual General Meeting in 2016).
In 2016 Biohit Oyj will publish the following financial reviews and annual report:
-
Financial statement release for 2015 on Thursday 25th of February 2016 at 9:30 AM
-
Annual report, including financial statements for 2015 and the Report of the Board of Directors, approximately during week 12
- Half-year report for period January - June 2016 (Q2) on Thursday 18th of August 2016 at 9:30 AM
The decision is based on the amendment of the Securities Markets Act entered into force on November 26, 2015. Following the amendment, listed companies no longer are obligated to disclose interim reports for the first three and nine months of the financial period.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com